✦ LIBER ✦

Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy

✍ Scribed by Chafika Mazouni; Angeline Hall; Kristine Broglio; Herbert Fritsche; Fabrice Andre; Francisco J. Esteva; Gabriel N. Hortobagyi; Aman U. Buzdar; Lajos Pusztai; Massimo Cristofanilli

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 105 KB
Volume: 109
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22418

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunohistochemical expression of HER1,

Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

✍ Kan Yonemori; Koji Tsuta; Chikako Shimizu; Yutaka Hatanaka; Akihiro Hirakawa; Ma 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

Increased risk of brain metastases in pa

Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma

✍ Ramin Altaha; Edward Crowell; Gerry Hobbs; Gerry Higa; Jame Abraham 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 2 views

Serum EGFR and serum HER-2/neu are usefu

Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy

✍ Maria Teresa Sandri; Harriet Ann Johansson; Laura Zorzino; Michela Salvatici; Ri 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

## Abstract ## BACKGROUND. Metronomic chemotherapy has been demonstrated to be of value in patients with advanced breast cancer. No reliable markers of response are available. In breast tumor, HER‐2/__neu__ is a prognostic factor, whereas no definite data exist for EGFR. The aim of the study was t

Hormone-receptor expression and activity

Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients

✍ Filippo Montemurro; Valentina Rossi; Maria Cossu Rocca; Rossella Martinello; Ele 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 223 KB 👁 2 views

C-Met overexpression in node-positive br

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

✍ Ernst Lengyel; Dieter Prechtel; James H. Resau; Katja Gauger; Anita Welk; Kristi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 296 KB

Receptor tyrosine kinases play an important role in malignant transformation of epithelial cells by activating signal transduction pathways important for proliferation, invasion and metastasis. In a pilot study (n ‫؍‬ 40), we evaluated expression of the c-Met and Her2/neu receptor tyrosine kinases a

Phase 2 randomized trial of primary endo

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

✍ Vladimir F. Semiglazov; Vladislav V. Semiglazov; Garik A. Dashyan; Elena K. Zilt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 194 KB

## Abstract ## BACKGROUND. Few studies have compared primary neoadjuvant endocrine therapy with neoadjuvant chemotherapy in breast cancer patients. The need for preoperative chemotherapy with doxorubicin or taxanes may be reduced in postmenopausal patients with estrogen receptor (ER)‐positive and/